Stefan Sillau
Concepts (416)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Parkinson Disease | 20 | 2024 | 325 | 2.390 |
Why?
| Palliative Care | 12 | 2024 | 642 | 0.950 |
Why?
| Multiple Sclerosis | 7 | 2023 | 380 | 0.900 |
Why?
| Caregivers | 9 | 2024 | 713 | 0.760 |
Why?
| Seizures | 8 | 2023 | 344 | 0.700 |
Why?
| Quality of Life | 15 | 2024 | 2385 | 0.680 |
Why?
| Alzheimer Disease | 5 | 2024 | 438 | 0.630 |
Why?
| Epilepsy | 4 | 2023 | 290 | 0.570 |
Why?
| Drug Resistant Epilepsy | 3 | 2023 | 46 | 0.570 |
Why?
| Natalizumab | 4 | 2021 | 46 | 0.530 |
Why?
| Parkinsonian Disorders | 3 | 2020 | 27 | 0.500 |
Why?
| Fingolimod Hydrochloride | 3 | 2020 | 30 | 0.490 |
Why?
| Humans | 93 | 2024 | 115587 | 0.430 |
Why?
| Immunologic Factors | 3 | 2020 | 220 | 0.430 |
Why?
| Atherosclerosis | 4 | 2019 | 341 | 0.410 |
Why?
| Ambulatory Care | 3 | 2020 | 478 | 0.400 |
Why?
| Diabetic Neuropathies | 2 | 2023 | 79 | 0.380 |
Why?
| Charcot-Marie-Tooth Disease | 2 | 2022 | 19 | 0.380 |
Why?
| Sinusitis | 3 | 2021 | 175 | 0.370 |
Why?
| Chagas Disease | 2 | 2021 | 34 | 0.360 |
Why?
| Music Therapy | 2 | 2021 | 21 | 0.360 |
Why?
| Male | 53 | 2024 | 55949 | 0.340 |
Why?
| Middle Aged | 37 | 2021 | 26999 | 0.340 |
Why?
| Aged | 31 | 2024 | 19251 | 0.340 |
Why?
| Retrospective Studies | 27 | 2024 | 12608 | 0.340 |
Why?
| Stroke, Lacunar | 2 | 2019 | 4 | 0.330 |
Why?
| Torticollis | 2 | 2019 | 12 | 0.330 |
Why?
| Female | 53 | 2023 | 59913 | 0.320 |
Why?
| Rituximab | 2 | 2020 | 149 | 0.320 |
Why?
| Multiple Sclerosis, Relapsing-Remitting | 2 | 2020 | 69 | 0.320 |
Why?
| Meningitis, Cryptococcal | 2 | 2019 | 28 | 0.320 |
Why?
| Dystonic Disorders | 2 | 2019 | 17 | 0.320 |
Why?
| Cardiomyopathies | 2 | 2021 | 303 | 0.290 |
Why?
| Spirituality | 4 | 2021 | 69 | 0.290 |
Why?
| Adult | 31 | 2023 | 30718 | 0.290 |
Why?
| Medical Staff, Hospital | 2 | 2021 | 74 | 0.280 |
Why?
| Myelitis | 2 | 2018 | 88 | 0.280 |
Why?
| Sepsis | 2 | 2022 | 515 | 0.260 |
Why?
| Neurosurgical Procedures | 2 | 2017 | 157 | 0.260 |
Why?
| Cognition | 5 | 2023 | 980 | 0.260 |
Why?
| Adaptation, Psychological | 5 | 2020 | 551 | 0.250 |
Why?
| Magnetic Resonance Imaging | 10 | 2024 | 3069 | 0.250 |
Why?
| Child Abuse | 2 | 2022 | 455 | 0.240 |
Why?
| Aged, 80 and over | 14 | 2021 | 6417 | 0.240 |
Why?
| Telemedicine | 2 | 2024 | 667 | 0.240 |
Why?
| Nasal Polyps | 2 | 2016 | 49 | 0.240 |
Why?
| Cerebral Amyloid Angiopathy | 1 | 2024 | 9 | 0.230 |
Why?
| Patient Care Team | 3 | 2019 | 521 | 0.230 |
Why?
| Cognition Disorders | 2 | 2018 | 475 | 0.230 |
Why?
| Cost of Illness | 3 | 2021 | 257 | 0.230 |
Why?
| Inpatients | 3 | 2021 | 380 | 0.230 |
Why?
| Dimethyl Fumarate | 2 | 2020 | 10 | 0.220 |
Why?
| Severity of Illness Index | 8 | 2020 | 2578 | 0.210 |
Why?
| Frontotemporal Dementia | 1 | 2022 | 20 | 0.210 |
Why?
| Sleep | 3 | 2021 | 625 | 0.210 |
Why?
| Apolipoprotein E4 | 1 | 2022 | 32 | 0.200 |
Why?
| Cannabidiol | 1 | 2023 | 59 | 0.200 |
Why?
| Vagus Nerve Stimulation | 1 | 2022 | 22 | 0.200 |
Why?
| Conversion Disorder | 1 | 2022 | 9 | 0.200 |
Why?
| Epilepsies, Partial | 1 | 2022 | 31 | 0.200 |
Why?
| Memory Consolidation | 1 | 2021 | 11 | 0.200 |
Why?
| Cross-Sectional Studies | 10 | 2021 | 4435 | 0.190 |
Why?
| Chagas Cardiomyopathy | 1 | 2021 | 22 | 0.190 |
Why?
| Risk Assessment | 6 | 2023 | 2987 | 0.190 |
Why?
| Motor Disorders | 1 | 2021 | 16 | 0.190 |
Why?
| Dermatitis, Seborrheic | 1 | 2020 | 4 | 0.190 |
Why?
| Disease Progression | 4 | 2022 | 2418 | 0.190 |
Why?
| Intellectual Disability | 1 | 2022 | 129 | 0.190 |
Why?
| Colorado | 11 | 2021 | 4113 | 0.190 |
Why?
| Attitude of Health Personnel | 2 | 2021 | 990 | 0.180 |
Why?
| Hospice and Palliative Care Nursing | 1 | 2022 | 69 | 0.180 |
Why?
| Treatment Outcome | 12 | 2022 | 9159 | 0.180 |
Why?
| Vitamin D | 2 | 2015 | 341 | 0.180 |
Why?
| Young Adult | 14 | 2022 | 10470 | 0.180 |
Why?
| Self Report | 3 | 2022 | 698 | 0.180 |
Why?
| Basal Ganglia Diseases | 1 | 2020 | 8 | 0.180 |
Why?
| Tumor Necrosis Factor-alpha | 2 | 2022 | 1137 | 0.180 |
Why?
| Electronic Health Records | 2 | 2021 | 805 | 0.180 |
Why?
| Terminal Care | 1 | 2023 | 212 | 0.180 |
Why?
| Cytokines | 3 | 2022 | 1853 | 0.180 |
Why?
| Multiple Sclerosis, Chronic Progressive | 1 | 2020 | 25 | 0.180 |
Why?
| Sphenoid Bone | 2 | 2016 | 15 | 0.180 |
Why?
| Interferon-gamma | 1 | 2023 | 726 | 0.170 |
Why?
| Neurovascular Coupling | 1 | 2019 | 7 | 0.170 |
Why?
| Diabetes Mellitus, Type 2 | 3 | 2023 | 2098 | 0.170 |
Why?
| Disabled Persons | 1 | 2021 | 135 | 0.170 |
Why?
| Shock, Septic | 1 | 2021 | 185 | 0.170 |
Why?
| Radiotherapy, Adjuvant | 2 | 2016 | 182 | 0.170 |
Why?
| Cognitive Dysfunction | 1 | 2023 | 279 | 0.170 |
Why?
| Behavioral Symptoms | 1 | 2019 | 40 | 0.170 |
Why?
| Down Syndrome | 2 | 2022 | 336 | 0.160 |
Why?
| Cohort Studies | 8 | 2021 | 4944 | 0.160 |
Why?
| Cannabinoids | 1 | 2020 | 116 | 0.160 |
Why?
| Streptococcal Infections | 1 | 2021 | 132 | 0.160 |
Why?
| Glatiramer Acetate | 1 | 2019 | 20 | 0.160 |
Why?
| Critical Care Outcomes | 1 | 2018 | 12 | 0.160 |
Why?
| Electroencephalography | 4 | 2022 | 365 | 0.160 |
Why?
| Psychotherapy, Group | 1 | 2019 | 61 | 0.160 |
Why?
| Psychometrics | 2 | 2019 | 615 | 0.160 |
Why?
| Diet, Ketogenic | 1 | 2018 | 33 | 0.160 |
Why?
| Restless Legs Syndrome | 1 | 2018 | 18 | 0.160 |
Why?
| Blepharospasm | 1 | 2018 | 7 | 0.160 |
Why?
| Fluoxetine | 1 | 2018 | 46 | 0.160 |
Why?
| Proxy | 1 | 2018 | 23 | 0.160 |
Why?
| Brain | 5 | 2022 | 2370 | 0.160 |
Why?
| Aftercare | 1 | 2020 | 187 | 0.150 |
Why?
| Basal Ganglia | 1 | 2018 | 42 | 0.150 |
Why?
| Subthalamic Nucleus | 1 | 2018 | 38 | 0.150 |
Why?
| Clinical Laboratory Techniques | 1 | 2018 | 87 | 0.150 |
Why?
| Immunosuppressive Agents | 2 | 2019 | 666 | 0.150 |
Why?
| Nutrition Surveys | 1 | 2019 | 225 | 0.150 |
Why?
| Central Nervous System Viral Diseases | 1 | 2018 | 63 | 0.150 |
Why?
| Neurology | 1 | 2019 | 85 | 0.150 |
Why?
| Autism Spectrum Disorder | 1 | 2022 | 322 | 0.150 |
Why?
| Ambulatory Care Facilities | 1 | 2019 | 211 | 0.150 |
Why?
| Hypoxia-Ischemia, Brain | 1 | 2017 | 26 | 0.150 |
Why?
| Transcranial Magnetic Stimulation | 1 | 2017 | 43 | 0.150 |
Why?
| Prevalence | 6 | 2022 | 2264 | 0.150 |
Why?
| Deep Brain Stimulation | 1 | 2018 | 71 | 0.150 |
Why?
| Neuromuscular Diseases | 1 | 2018 | 90 | 0.140 |
Why?
| Follow-Up Studies | 7 | 2020 | 4440 | 0.140 |
Why?
| Cranial Nerve Diseases | 1 | 2017 | 42 | 0.140 |
Why?
| Immunoglobulin G | 1 | 2021 | 781 | 0.140 |
Why?
| Interprofessional Relations | 1 | 2019 | 258 | 0.140 |
Why?
| Movement Disorders | 1 | 2017 | 46 | 0.140 |
Why?
| Medical Marijuana | 1 | 2018 | 97 | 0.140 |
Why?
| Adolescent | 13 | 2023 | 17889 | 0.140 |
Why?
| Cannabis | 1 | 2023 | 381 | 0.140 |
Why?
| Orbital Diseases | 1 | 2016 | 25 | 0.140 |
Why?
| Dementia | 1 | 2019 | 185 | 0.140 |
Why?
| Muscular Diseases | 1 | 2017 | 104 | 0.140 |
Why?
| Giant Cell Tumor of Bone | 1 | 2016 | 6 | 0.140 |
Why?
| Atrophy | 3 | 2024 | 152 | 0.140 |
Why?
| Child | 13 | 2022 | 18488 | 0.140 |
Why?
| Cerebellum | 1 | 2018 | 200 | 0.140 |
Why?
| Craniocerebral Trauma | 1 | 2017 | 129 | 0.130 |
Why?
| Skull Base Neoplasms | 1 | 2016 | 26 | 0.130 |
Why?
| Models, Theoretical | 1 | 2020 | 519 | 0.130 |
Why?
| Meningioma | 1 | 2016 | 78 | 0.130 |
Why?
| Radiotherapy, Intensity-Modulated | 1 | 2016 | 123 | 0.130 |
Why?
| T-Lymphocytes | 1 | 2023 | 1756 | 0.130 |
Why?
| Longitudinal Studies | 3 | 2022 | 2416 | 0.130 |
Why?
| Meningeal Neoplasms | 1 | 2016 | 88 | 0.130 |
Why?
| Burnout, Professional | 1 | 2021 | 322 | 0.130 |
Why?
| Risk Factors | 9 | 2019 | 8697 | 0.130 |
Why?
| Marijuana Smoking | 1 | 2018 | 224 | 0.130 |
Why?
| Regression Analysis | 2 | 2018 | 959 | 0.120 |
Why?
| Hemodynamics | 1 | 2019 | 968 | 0.120 |
Why?
| Education, Medical, Graduate | 1 | 2019 | 376 | 0.120 |
Why?
| Motor Activity | 1 | 2019 | 633 | 0.120 |
Why?
| Stroke | 2 | 2020 | 1016 | 0.120 |
Why?
| Craniofacial Abnormalities | 1 | 2015 | 59 | 0.120 |
Why?
| Physicians | 1 | 2023 | 776 | 0.120 |
Why?
| Patient Readmission | 1 | 2020 | 609 | 0.120 |
Why?
| Data Collection | 2 | 2022 | 636 | 0.120 |
Why?
| Aspirin | 2 | 2016 | 326 | 0.120 |
Why?
| Rhinitis | 1 | 2016 | 128 | 0.120 |
Why?
| Retinopathy of Prematurity | 1 | 2016 | 111 | 0.120 |
Why?
| Neonatal Screening | 1 | 2016 | 151 | 0.120 |
Why?
| Neuropsychological Tests | 1 | 2018 | 919 | 0.120 |
Why?
| Neoplasm Recurrence, Local | 2 | 2016 | 863 | 0.120 |
Why?
| Anxiety Disorders | 1 | 2017 | 310 | 0.120 |
Why?
| Vitamin D Deficiency | 2 | 2015 | 159 | 0.120 |
Why?
| Urolithiasis | 1 | 2014 | 8 | 0.120 |
Why?
| Ureteroscopy | 1 | 2014 | 16 | 0.120 |
Why?
| Depressive Disorder | 1 | 2017 | 336 | 0.120 |
Why?
| Eosinophilia | 1 | 2016 | 186 | 0.110 |
Why?
| Chronic Disease | 2 | 2016 | 1598 | 0.110 |
Why?
| Behavioral Medicine | 1 | 2014 | 37 | 0.110 |
Why?
| Patient-Centered Care | 1 | 2019 | 477 | 0.110 |
Why?
| Mental Disorders | 1 | 2021 | 902 | 0.110 |
Why?
| Extremities | 1 | 2014 | 113 | 0.110 |
Why?
| Nervous System Diseases | 1 | 2016 | 253 | 0.110 |
Why?
| Tonsillectomy | 1 | 2015 | 72 | 0.110 |
Why?
| Prognosis | 4 | 2023 | 3339 | 0.110 |
Why?
| Rural Health Services | 1 | 2014 | 93 | 0.110 |
Why?
| Refugees | 1 | 2014 | 53 | 0.110 |
Why?
| Pulmonary Ventilation | 1 | 2013 | 68 | 0.110 |
Why?
| Primary Prevention | 1 | 2015 | 171 | 0.110 |
Why?
| Demography | 1 | 2014 | 261 | 0.110 |
Why?
| Tomography, X-Ray Computed | 4 | 2016 | 2392 | 0.110 |
Why?
| Antiviral Agents | 1 | 2018 | 651 | 0.110 |
Why?
| Incidence | 4 | 2022 | 2335 | 0.110 |
Why?
| Birth Weight | 1 | 2016 | 438 | 0.110 |
Why?
| Airway Obstruction | 1 | 2015 | 168 | 0.110 |
Why?
| Weight Gain | 1 | 2016 | 453 | 0.100 |
Why?
| Curriculum | 1 | 2019 | 852 | 0.100 |
Why?
| Movement | 1 | 2014 | 246 | 0.100 |
Why?
| Coronary Vessels | 1 | 2014 | 229 | 0.100 |
Why?
| Teaching Rounds | 1 | 2013 | 64 | 0.100 |
Why?
| Depression | 1 | 2020 | 1145 | 0.100 |
Why?
| Coronary Disease | 1 | 2014 | 348 | 0.100 |
Why?
| Calcinosis | 1 | 2014 | 242 | 0.100 |
Why?
| Sleep Apnea, Obstructive | 1 | 2015 | 194 | 0.100 |
Why?
| Tissue Donors | 1 | 2014 | 331 | 0.100 |
Why?
| Environmental Monitoring | 1 | 2013 | 260 | 0.100 |
Why?
| Delivery of Health Care, Integrated | 1 | 2014 | 231 | 0.100 |
Why?
| Reproducibility of Results | 4 | 2022 | 2800 | 0.090 |
Why?
| Internal Medicine | 1 | 2013 | 211 | 0.090 |
Why?
| Surveys and Questionnaires | 6 | 2019 | 4665 | 0.090 |
Why?
| Interpersonal Relations | 1 | 2014 | 342 | 0.090 |
Why?
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2015 | 373 | 0.090 |
Why?
| Obesity | 2 | 2021 | 2517 | 0.090 |
Why?
| Amyloid beta-Peptides | 2 | 2023 | 191 | 0.090 |
Why?
| Tissue and Organ Procurement | 1 | 2014 | 243 | 0.090 |
Why?
| Family | 1 | 2014 | 594 | 0.090 |
Why?
| United States | 7 | 2022 | 12295 | 0.090 |
Why?
| Polysomnography | 3 | 2015 | 135 | 0.090 |
Why?
| Patient Outcome Assessment | 2 | 2023 | 123 | 0.090 |
Why?
| Time Factors | 5 | 2020 | 6165 | 0.090 |
Why?
| Cross Infection | 1 | 2012 | 202 | 0.090 |
Why?
| Case-Control Studies | 3 | 2023 | 3022 | 0.090 |
Why?
| Postoperative Complications | 2 | 2017 | 2161 | 0.090 |
Why?
| Models, Statistical | 1 | 2013 | 606 | 0.080 |
Why?
| Brain Neoplasms | 1 | 2017 | 980 | 0.080 |
Why?
| Internship and Residency | 1 | 2019 | 951 | 0.080 |
Why?
| Phenotype | 1 | 2017 | 2829 | 0.080 |
Why?
| Cardiac Surgical Procedures | 1 | 2013 | 413 | 0.080 |
Why?
| Health Status | 1 | 2014 | 728 | 0.080 |
Why?
| Coronary Artery Disease | 1 | 2015 | 607 | 0.080 |
Why?
| Quality of Health Care | 1 | 2013 | 576 | 0.080 |
Why?
| Calcium | 1 | 2014 | 1103 | 0.080 |
Why?
| Blood Pressure | 1 | 2014 | 1537 | 0.080 |
Why?
| Prospective Studies | 5 | 2023 | 6264 | 0.080 |
Why?
| Muscle, Skeletal | 1 | 2017 | 1447 | 0.080 |
Why?
| Intensive Care Units | 1 | 2012 | 622 | 0.070 |
Why?
| Health Services Accessibility | 1 | 2014 | 771 | 0.070 |
Why?
| Length of Stay | 1 | 2012 | 958 | 0.070 |
Why?
| Patient Participation | 2 | 2022 | 363 | 0.070 |
Why?
| Internet | 1 | 2011 | 602 | 0.070 |
Why?
| Heart Defects, Congenital | 1 | 2013 | 659 | 0.070 |
Why?
| Critical Illness | 1 | 2012 | 645 | 0.070 |
Why?
| Lung Diseases | 1 | 2013 | 710 | 0.070 |
Why?
| Double-Blind Method | 2 | 2023 | 1660 | 0.070 |
Why?
| Asthma | 3 | 2016 | 2066 | 0.070 |
Why?
| Recurrence | 2 | 2020 | 952 | 0.070 |
Why?
| Feasibility Studies | 2 | 2019 | 741 | 0.070 |
Why?
| Hypertension | 1 | 2014 | 1064 | 0.070 |
Why?
| Influenza, Human | 1 | 2011 | 548 | 0.070 |
Why?
| Survival Analysis | 2 | 2019 | 1219 | 0.060 |
Why?
| Health Knowledge, Attitudes, Practice | 1 | 2014 | 1198 | 0.060 |
Why?
| Child, Preschool | 4 | 2020 | 9133 | 0.060 |
Why?
| Randomized Controlled Trials as Topic | 2 | 2021 | 1216 | 0.060 |
Why?
| Sleep Wake Disorders | 2 | 2019 | 233 | 0.060 |
Why?
| Research Design | 2 | 2021 | 946 | 0.060 |
Why?
| Anxiety | 2 | 2021 | 853 | 0.060 |
Why?
| Primary Health Care | 1 | 2014 | 1518 | 0.060 |
Why?
| Comorbidity | 2 | 2021 | 1473 | 0.060 |
Why?
| Neurologists | 1 | 2024 | 18 | 0.060 |
Why?
| Pandemics | 2 | 2022 | 1334 | 0.060 |
Why?
| Amyloidogenic Proteins | 1 | 2023 | 9 | 0.060 |
Why?
| Vaccination | 1 | 2011 | 1209 | 0.060 |
Why?
| Sensitivity and Specificity | 2 | 2020 | 1718 | 0.060 |
Why?
| Intermediate Filaments | 1 | 2023 | 46 | 0.060 |
Why?
| Neurofilament Proteins | 1 | 2023 | 34 | 0.050 |
Why?
| Cerebral Hemorrhage | 1 | 2024 | 96 | 0.050 |
Why?
| Biomarkers | 2 | 2023 | 3466 | 0.050 |
Why?
| tau Proteins | 1 | 2023 | 67 | 0.050 |
Why?
| Myelin P0 Protein | 1 | 2022 | 7 | 0.050 |
Why?
| Imipramine | 1 | 2022 | 12 | 0.050 |
Why?
| Hypertension, Pulmonary | 1 | 2013 | 1749 | 0.050 |
Why?
| Pain | 2 | 2018 | 712 | 0.050 |
Why?
| Facial Expression | 1 | 2022 | 60 | 0.050 |
Why?
| Infusions, Intravenous | 1 | 2023 | 374 | 0.050 |
Why?
| Dronabinol | 1 | 2023 | 118 | 0.050 |
Why?
| Inflammation | 2 | 2022 | 2499 | 0.050 |
Why?
| Healthy Volunteers | 1 | 2022 | 192 | 0.050 |
Why?
| Polymerization | 1 | 2022 | 119 | 0.050 |
Why?
| Predictive Value of Tests | 2 | 2019 | 1805 | 0.050 |
Why?
| Vagus Nerve | 1 | 2022 | 82 | 0.050 |
Why?
| Reference Standards | 1 | 2022 | 161 | 0.050 |
Why?
| Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2022 | 140 | 0.050 |
Why?
| Streptococcus anginosus | 1 | 2021 | 9 | 0.050 |
Why?
| Catalysis | 1 | 2022 | 299 | 0.050 |
Why?
| Oncology Service, Hospital | 1 | 2021 | 14 | 0.050 |
Why?
| Interneurons | 1 | 2022 | 99 | 0.050 |
Why?
| Lung | 1 | 2013 | 3672 | 0.050 |
Why?
| Outpatients | 1 | 2024 | 330 | 0.050 |
Why?
| Meta-Analysis as Topic | 1 | 2021 | 161 | 0.050 |
Why?
| Immune System | 1 | 2022 | 173 | 0.050 |
Why?
| Hospitals, University | 1 | 2021 | 172 | 0.050 |
Why?
| Longevity | 1 | 2021 | 136 | 0.050 |
Why?
| Reaction Time | 1 | 2022 | 373 | 0.040 |
Why?
| Astrocytes | 1 | 2022 | 163 | 0.040 |
Why?
| Serine | 1 | 2021 | 125 | 0.040 |
Why?
| Infant | 3 | 2018 | 7979 | 0.040 |
Why?
| Medical Informatics | 1 | 2021 | 93 | 0.040 |
Why?
| Antibodies, Viral | 1 | 2023 | 527 | 0.040 |
Why?
| Efficiency, Organizational | 1 | 2021 | 126 | 0.040 |
Why?
| Electrodes, Implanted | 1 | 2020 | 92 | 0.040 |
Why?
| Monitoring, Physiologic | 1 | 2022 | 250 | 0.040 |
Why?
| Age Distribution | 1 | 2020 | 341 | 0.040 |
Why?
| Multiple System Atrophy | 1 | 2019 | 4 | 0.040 |
Why?
| Sex Distribution | 1 | 2020 | 337 | 0.040 |
Why?
| Supranuclear Palsy, Progressive | 1 | 2019 | 5 | 0.040 |
Why?
| Developmental Disabilities | 1 | 2022 | 240 | 0.040 |
Why?
| Income | 1 | 2020 | 170 | 0.040 |
Why?
| Peptide Fragments | 1 | 2023 | 675 | 0.040 |
Why?
| Lewy Body Disease | 1 | 2019 | 16 | 0.040 |
Why?
| Maintenance Chemotherapy | 1 | 2019 | 22 | 0.040 |
Why?
| Music | 1 | 2019 | 35 | 0.040 |
Why?
| Pragmatic Clinical Trials as Topic | 1 | 2019 | 48 | 0.040 |
Why?
| Stroke Volume | 1 | 2021 | 509 | 0.040 |
Why?
| Qualitative Research | 1 | 2024 | 971 | 0.040 |
Why?
| Induction Chemotherapy | 1 | 2019 | 56 | 0.040 |
Why?
| Logistic Models | 2 | 2014 | 1856 | 0.040 |
Why?
| Gait | 1 | 2021 | 249 | 0.040 |
Why?
| Symptom Assessment | 1 | 2019 | 121 | 0.040 |
Why?
| Carnitine | 1 | 2018 | 61 | 0.040 |
Why?
| Antibodies, Monoclonal, Humanized | 1 | 2023 | 667 | 0.040 |
Why?
| Administration, Oral | 1 | 2020 | 734 | 0.040 |
Why?
| Tandem Mass Spectrometry | 1 | 2021 | 414 | 0.040 |
Why?
| B-Lymphocytes | 1 | 2023 | 773 | 0.040 |
Why?
| Ventricular Function, Left | 1 | 2021 | 467 | 0.040 |
Why?
| Phosphorus | 1 | 2018 | 81 | 0.040 |
Why?
| Demyelinating Diseases | 1 | 2019 | 75 | 0.040 |
Why?
| Age of Onset | 1 | 2019 | 450 | 0.040 |
Why?
| Muscle Spasticity | 1 | 2018 | 53 | 0.040 |
Why?
| Comparative Effectiveness Research | 1 | 2019 | 130 | 0.040 |
Why?
| Arrhythmias, Cardiac | 1 | 2020 | 279 | 0.040 |
Why?
| Health Services | 1 | 2019 | 104 | 0.040 |
Why?
| Neural Pathways | 1 | 2019 | 260 | 0.040 |
Why?
| Diffusion Tensor Imaging | 1 | 2018 | 66 | 0.040 |
Why?
| Gadolinium | 1 | 2018 | 78 | 0.040 |
Why?
| Emotions | 1 | 2022 | 477 | 0.040 |
Why?
| Hippocampus | 1 | 2022 | 709 | 0.040 |
Why?
| Sex Characteristics | 1 | 2022 | 641 | 0.040 |
Why?
| Neural Conduction | 1 | 2017 | 79 | 0.040 |
Why?
| ROC Curve | 1 | 2018 | 451 | 0.040 |
Why?
| Disability Evaluation | 1 | 2019 | 271 | 0.040 |
Why?
| Exophthalmos | 1 | 2016 | 19 | 0.040 |
Why?
| Neuroimaging | 1 | 2019 | 247 | 0.030 |
Why?
| Temporomandibular Joint | 1 | 2016 | 10 | 0.030 |
Why?
| Frontal Bone | 1 | 2016 | 13 | 0.030 |
Why?
| Sex Factors | 1 | 2022 | 1736 | 0.030 |
Why?
| Cranial Fossa, Middle | 1 | 2016 | 7 | 0.030 |
Why?
| Brain Ischemia | 1 | 2020 | 298 | 0.030 |
Why?
| Occipital Bone | 1 | 2016 | 18 | 0.030 |
Why?
| Interviews as Topic | 1 | 2019 | 596 | 0.030 |
Why?
| Intraoperative Complications | 1 | 2017 | 126 | 0.030 |
Why?
| Brain Mapping | 1 | 2019 | 521 | 0.030 |
Why?
| Temporal Bone | 1 | 2016 | 44 | 0.030 |
Why?
| Neoplasm Grading | 1 | 2016 | 244 | 0.030 |
Why?
| Drug Administration Schedule | 1 | 2018 | 724 | 0.030 |
Why?
| Self Efficacy | 1 | 2019 | 361 | 0.030 |
Why?
| Activities of Daily Living | 1 | 2018 | 352 | 0.030 |
Why?
| Neoplasm, Residual | 1 | 2016 | 105 | 0.030 |
Why?
| Electromyography | 1 | 2017 | 324 | 0.030 |
Why?
| Anticonvulsants | 1 | 2017 | 181 | 0.030 |
Why?
| Sleep Stages | 1 | 2015 | 61 | 0.030 |
Why?
| Contrast Media | 1 | 2018 | 362 | 0.030 |
Why?
| Patient Reported Outcome Measures | 1 | 2017 | 250 | 0.030 |
Why?
| Actigraphy | 1 | 2015 | 73 | 0.030 |
Why?
| Psychiatric Status Rating Scales | 1 | 2017 | 485 | 0.030 |
Why?
| Infant, Newborn | 2 | 2016 | 5077 | 0.030 |
Why?
| Pilot Projects | 1 | 2019 | 1377 | 0.030 |
Why?
| Drug Hypersensitivity | 1 | 2016 | 86 | 0.030 |
Why?
| Age Factors | 1 | 2022 | 2907 | 0.030 |
Why?
| Thinness | 1 | 2015 | 87 | 0.030 |
Why?
| Adenoidectomy | 1 | 2015 | 60 | 0.030 |
Why?
| Sleep Apnea Syndromes | 1 | 2015 | 74 | 0.030 |
Why?
| San Francisco | 1 | 2014 | 56 | 0.030 |
Why?
| Sampling Studies | 1 | 2014 | 95 | 0.030 |
Why?
| Combined Modality Therapy | 1 | 2016 | 1127 | 0.030 |
Why?
| False Positive Reactions | 1 | 2014 | 109 | 0.030 |
Why?
| Sternotomy | 1 | 2013 | 18 | 0.030 |
Why?
| Biopsy | 1 | 2017 | 1056 | 0.030 |
Why?
| Critical Care | 1 | 2017 | 477 | 0.030 |
Why?
| Lithotripsy | 1 | 2014 | 40 | 0.030 |
Why?
| Physician-Nurse Relations | 1 | 2013 | 15 | 0.030 |
Why?
| Pulmonary Gas Exchange | 1 | 2013 | 113 | 0.030 |
Why?
| Odds Ratio | 1 | 2016 | 962 | 0.030 |
Why?
| Leukotriene E4 | 1 | 2013 | 27 | 0.030 |
Why?
| Thoracotomy | 1 | 2013 | 67 | 0.030 |
Why?
| Patient Acceptance of Health Care | 1 | 2019 | 682 | 0.030 |
Why?
| Monte Carlo Method | 1 | 2013 | 140 | 0.030 |
Why?
| Gestational Age | 1 | 2016 | 757 | 0.030 |
Why?
| Spirometry | 1 | 2013 | 253 | 0.030 |
Why?
| Paranasal Sinuses | 1 | 2013 | 66 | 0.030 |
Why?
| Linear Models | 1 | 2015 | 776 | 0.030 |
Why?
| Hospitals, Teaching | 1 | 2013 | 103 | 0.030 |
Why?
| Olfaction Disorders | 1 | 2013 | 48 | 0.030 |
Why?
| Drug Resistance | 1 | 2013 | 162 | 0.030 |
Why?
| Diabetic Angiopathies | 1 | 2015 | 244 | 0.030 |
Why?
| Vital Capacity | 1 | 2013 | 277 | 0.030 |
Why?
| Disease Models, Animal | 1 | 2022 | 3580 | 0.030 |
Why?
| Disease-Free Survival | 1 | 2014 | 621 | 0.030 |
Why?
| Mutation | 1 | 2022 | 3364 | 0.030 |
Why?
| Paper | 1 | 2011 | 8 | 0.030 |
Why?
| Coronary Angiography | 1 | 2014 | 307 | 0.030 |
Why?
| Forced Expiratory Volume | 1 | 2013 | 516 | 0.020 |
Why?
| Health Care Surveys | 1 | 2014 | 538 | 0.020 |
Why?
| Particulate Matter | 1 | 2013 | 183 | 0.020 |
Why?
| Personnel, Hospital | 1 | 2011 | 24 | 0.020 |
Why?
| Premature Birth | 1 | 2015 | 278 | 0.020 |
Why?
| Aging | 1 | 2021 | 1631 | 0.020 |
Why?
| Confidence Intervals | 1 | 2012 | 309 | 0.020 |
Why?
| Urban Population | 1 | 2014 | 405 | 0.020 |
Why?
| Eosinophils | 1 | 2013 | 282 | 0.020 |
Why?
| Oxygen Consumption | 1 | 2013 | 573 | 0.020 |
Why?
| Exercise Test | 1 | 2013 | 539 | 0.020 |
Why?
| Tobacco Smoke Pollution | 1 | 2013 | 221 | 0.020 |
Why?
| Patient Admission | 1 | 2012 | 175 | 0.020 |
Why?
| Cause of Death | 1 | 2012 | 368 | 0.020 |
Why?
| Socioeconomic Factors | 1 | 2014 | 1086 | 0.020 |
Why?
| Recovery of Function | 1 | 2013 | 577 | 0.020 |
Why?
| Computer Simulation | 1 | 2013 | 881 | 0.020 |
Why?
| Proportional Hazards Models | 1 | 2012 | 1087 | 0.020 |
Why?
| Models, Biological | 1 | 2016 | 1646 | 0.020 |
Why?
| Algorithms | 1 | 2016 | 1490 | 0.020 |
Why?
| Healthcare Disparities | 1 | 2014 | 485 | 0.020 |
Why?
| Practice Guidelines as Topic | 1 | 2015 | 1405 | 0.020 |
Why?
| Influenza Vaccines | 1 | 2011 | 498 | 0.020 |
Why?
| Patient Discharge | 1 | 2012 | 770 | 0.020 |
Why?
| Mice | 1 | 2022 | 15052 | 0.020 |
Why?
| Animals | 1 | 2022 | 32102 | 0.010 |
Why?
|
|
Sillau's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|